corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 2400

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: Journal Article

Helft PR, Ratain MJ, Epstein RA, Siegler M.
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
J Natl Cancer Inst 2004 May 5; 96:(9):656-61
http://jncicancerspectrum.oxfordjournals.org/cgi/content/full/jnci;96/9/656


Abstract:

In recent years, several research subjects have told us that they had bought or intended to buy stock in the companies sponsoring the clinical trials in which they were enrolled. This situation has led us to ask what, if any, are physician-investigators’ scientific, ethical, and legal responsibilities concerning research subjects who choose to buy stock in the companies sponsoring the clinical trials in which they are participating. Although the scope of this problem is unknown and is likely to be small, this commentary examines the scientific, ethical, and legal concerns raised by such activities on the part of research subjects enrolled in early phase clinical trials. In addition, this commentary also outlines the basis for our opinion that research subjects involved in an early phase clinical trial should avoid the financial conflicts of interest created by trading stock in the company sponsoring the clinical trial.

Keywords:
Publication Types: Review Review, Tutorial MeSH Terms: Clinical Trials, Phase I*/economics Clinical Trials, Phase I*/ethics Clinical Trials, Phase I*/legislation & jurisprudence Conflict of Interest* Drug Industry*/economics Drug Industry*/ethics Drug Industry*/legislation & jurisprudence Drugs, Investigational*/adverse effects Drugs, Investigational*/economics Drugs, Investigational*/standards Ethics, Research* Humans Information Dissemination*/ethics Information Dissemination*/legislation & jurisprudence Informed Consent Physician-Patient Relations Research Subjects*/economics Research Subjects*/legislation & jurisprudence Research Support* United States Substances: Drugs, Investigational

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.